blindness from glp-1 NAION Vision Loss Lawsuit There's been a lot of
Description
The currently approved pharmaceutical strategies targeted to the GLP-1 system are aimed at either increasing endogenous GLP-1 levels with inhibitors for the protease that inactivates GLP-1 or long-acting GLP-1r agonists resistant to DPP4 cleavage (2, 51)
GLP-1 Clinical Practice Updates: August 2025 Key Developments August 2025 delivered significant clinical practice updates that advance the GLP-1 treatment landscape, including the first generic approval, expanded FDA indications, and major oral therapy breakthroughs
prophylactic measures in high-risk individuals may be considered [8,9]
(2022) GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation
